Randomized controlled trial of neoadjuvant chemotherapy plus surgery versus neoadjuvant chemoradiotherapy plus surgery in patients with clinical stage IIB-III esophageal carcinoma (Subset analyses depending on the REG I expression in the tumor)

Randomized controlled trial of neoadjuvant chemotherapy plus surgery versus neoadjuvant chemoradiotherapy plus surgery in patients with clinical stage IIB-III esophageal carcinoma (Subset analyses depending on the REG I expression in the tumor) - Controll trial of neoadjuvant chemotherapy versus chemoradiotherapy in patients with esophageal carcinoma

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004707

Enrollment

150

Registered

2010-12-12

Start date

2010-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thoracic esophageal cancer

Interventions

neoadjuvant chemotherapy neoadjuvant chemoradiotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) primary squamous cell carcinoma in the thoracic esophagus (2) clinical stage IIB-III(Non T4) (3) ECOG-PS 0,1 (4) Cr<=1.2 mg/dl, BUN<=25 mg/dl, 24hCCr<=60 ml/min, T.Bil<=1.2 mg/dl, GOT and GPT<100 IU, WBC>=4,000 /mm3, Hb>=10 g/dl, Plt>=100,000 /mm3, PaO2>=70 torr (5 ) obtained an informed consent

Exclusion criteria

Exclusion criteria: (1) treatment history of chemotherapy or radiotherapy

Design outcomes

Primary

Measure	Time frame
overall survival	—

Secondary

Measure	Time frame
overall survival depending on the REG I expression in the tumor	—

Countries

Japan

Contacts

Public ContactNaoki Sasaki

Akita University School of Medicine Department of General Affairs

018-884-6008

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026